A promising drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half, according to new research led by Cleveland Clinic. Very limited therapies are currently available for this disabling form of the disease. The definitive results of the phase 2 trial – published in the New England Journal of Medicine – showed that the drug ibudilast decreased progression of brain atrophy in progressive MS patients by 48 percent versus placebo.
Cleveland Clinic researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the individualized nature of the disease. The findings, published in The Lancet Neurology, could potentially lead to more personalized diagnosis and treatments.